Release of Draft (Step 2) International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) Guidance


The online consultation is now closed. The content found on this page is a snapshot of the live consultation as it was presented to the public and contains the content that was open for submissions during the consultation period.

February 5, 2013


Our file number: 13-101302-66

The above referenced draft guidance was released by the ICH Steering Committee for consultation and is being posted on the Health Canada websiteFootnote 1 for information and comment in accordance with Step 2 of the ICH process.

Please note that draft guidance documents are only made available in English until finalized by the ICH. It is also important to note that amendments to draft documents may occur as a result of regulatory consultations and subsequent deliberations within the ICH.

All comments forwarded to Health Canada will be transmitted to the ICH as is, with the disclaimer that they are provided for information and do not necessarily represent the views of Health Canada, except as specifically indicated in separate comments.

As appropriate, your organization may alternatively wish to provide comments to your affiliate association in the U.S., Europe or Japan for their input directly to ICH.

Comments provided to Health Canada should be submitted no later than 90 days in order to allow sufficient time for their assessment and subsequent transmission to the ICH.

Comments should be directed to:

Celia Lourenco
Office of Clinical Trials
Therapeutic Products Directorate
Health Products and Food Branch
Health Canada
1600 Scott Street, Holland Cross
Ottawa, Ontario
K1A 0K9

Telephone: 613-954-6494
Fax: 613-952-9656

Page details

Date modified: